Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adventa BhdXKLS:7191 29 Debt-to-EBITDA is -3.99 as of Mar. 2026. GuruFocus rates XKLS:7191 with a GF Score™ of 29/100 and a GF Value™ of RM0.24 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Adventa Bhd ranks worse than 214592.06% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Adventa Bhd's Debt-to-EBITDA or its related term are showing as below:
XKLS:7191'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -12.01 Med: 0.22 Max: 6.07
Current: -6.79
During the past 13 years, the highest Debt-to-EBITDA Ratio of Adventa Bhd was 6.07. The lowest was -12.01. And the median was 0.22.
XKLS:7191's Debt-to-EBITDA is ranked worse than 100% of 466
companies
in the Medical Devices & Instruments industry
Industry Median: 1.585
vs XKLS:7191: -6.79
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Adventa Bhd Debt-to-EBITDA Related Terms
Adventa Bhd Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Adventa Bhd's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:7191 vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Adventa Bhd's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adventa Bhd Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Adventa Bhd's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Adventa Bhd's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Adventa Bhd (XKLS:7191) has a Debt-to-EBITDA of -3.99 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Adventa Bhd. According to the industry distribution chart, Adventa Bhd ranks #999999 out of 466 companies in the Medical Devices & Instruments industry.
Is Adventa Bhd's Debt-to-EBITDA too high?
Adventa Bhd's current Debt-to-EBITDA is -3.99. Based on the distribution chart, Adventa Bhd ranks #999999 out of 466 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Adventa Bhd has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Adventa Bhd's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Adventa Bhd ranks #999999 out of 466 companies for Debt-to-EBITDA. This places Adventa Bhd in the lower half of its industry. The industry median Debt-to-EBITDA is 1.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.59, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Adventa Bhd. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adventa Bhd's current Debt-to-EBITDA is -3.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adventa Bhd stock overvalued right now?
Based on GuruFocus' analysis, Adventa Bhd (XKLS:7191) is currently considered Possible Value Trap. The stock's GF Value™ is RM0.24, compared to a current price of RM0.12 — trading 50% below its estimated fair value. The current Debt-to-EBITDA is -3.99. Adventa Bhd's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Adventa Bhd (XKLS:7191), the current Debt-to-EBITDA is -3.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adventa Bhd (XKLS:7191) Overvalued in 2026?
Based on GuruFocus' analysis, Adventa Bhd stock appears to be undervalued.
The current stock price of RM0.12 is trading 50% below its estimated GF Value™ of RM0.24.
GuruFocus considers Adventa Bhd to be Possible Value Trap.
Key valuation signals for XKLS:7191:
Debt-to-EBITDA: -3.99
GF Value™: RM0.24 vs. price of RM0.12 (50% below fair value)
No single metric tells the full story. See the XKLS:7191 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adventa Bhd is engaged in investment holdings, management services, warehousing services, and the manufacturing, distribution, and supply of medical and healthcare equipment, appliances, and medical disposal products. It operates as a regional healthcare group focused on medical innovation, manufacturing excellence, and patient-centered solutions. Its segments include Investment Holdings, which involves investment in companies; Healthcare Products, which involves the manufacturing and supply of healthcare-related products and services to hospitals, healthcare centres, and pharmacies and generates maximum revenue; and Warehousing Provider, which provides storage and warehousing services. The company generates maximum revenue from Malaysia, followed by Indonesia and other countries.
29GF Score
Get the complete analysis for XKLS:7191
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7191 has been successfully added to your 
